Figure 2.

A. Relative body weight of mice treated witherlotinib15mg/kg daily, 30mg/kg daily, 50mg/kg daily, 100mg/kg daily, 200mg/kg every 4^th day, 200mg/kg every 2^nd day or vehicle detergent alone. Shown is the mean weight of mice, set relative to the weight at the beginning of the therapy. In B. mean plasma concentrations of erlotinib ±SD in mice are shown. Non-tumor harboring mice were treated orally with a single dose of either 30mg/kg or 200mg/kg and blood samples were taken from the tail-vein. Plasma-concentrations were determined by liquid chromatography tandem mass spectrometry. C. Mean erlotinib concentrations ±SD in tumor lysates (HCC827, PC9, H1975) or lysates of muscle tissue of mice treated with a single dose of either 30mg/kg or 200mg/kg erlotinib are shown. Lysates were prepared from untreated mice or 6, 12, 24 or 48 hours after administration of erlotinib. Erlotinib concentrations in the supernatant were assessed by mass spectrometry and set relative to the protein-amount of the lysate.*p < 0.05. D. Representative IHC-stainings for pEGFR of tumors (HCC827, PC9, H1975) of mice either untreated or treated with a single dose of 30mg/kg or 200mg/kg erlotinib. Tumors were resected 12 hours after treatment. 5x magnification, blue scale bar indicates 500μm.